Policy

Neurizon Therapeutics (ASX:NUZ) has announced the successful registration of its NEURIZON trademark across all major pharmaceutical markets.

Mesoblast (ASX:MSB) announced that the U.S. FDA acknowledged that clinical trial data demonstrate meaningful and sustained reductions in chronic low back pain, with the potential to reduce accompanying opioid use.

Telix Pharmaceuticals (ASX:TLX) has taken a significant step toward expanding access to advanced prostate cancer imaging in China, with the country’s drug regulator formally accepting a new drug application for the company’s lead diagnostic product, Illuccix.

Immuron (ASX:IMC) has reported continued sales growth across its key markets, underscoring the expanding global footprint of its flagship over-the-counter immune supplement, Travelan.

Zelira Therapeutics (ASX:ZLD) has taken a significant step forward in its mission to deliver clinically validated cannabinoid-based medicines, announcing a US$32.98 million capital raise into its HOPE 1 special purpose vehicle.

Australian radiopharmaceutical company Cyclopharm (ASX:CYC) has achieved a significant milestone in its US expansion, with Lucile Packard Children’s Hospital Stanford set to implement Technegas for paediatric lung imaging.

AusBiotech has been named as one of the national peak bodies selected to join the Australian Government’s newly established Trade Diversification Network.

Neuren Pharmaceuticals (ASX:NEU) has entered 2026 with growing confidence in the global trajectory of DAYBUE, its first-in-class treatment for Rett syndrome, as new data and commercial milestones continue to accumulate.

HaemaLogiX has appointed Dr Chris Baldwin as Chief Executive Officer and Managing Director, marking a significant leadership transition as the company prepares for its next stage of clinical and corporate development.

Radiopharm Theranostics (ASX:RAD) has increased its ownership stake in Radiopharm Ventures, LLC, the company’s joint venture with The University of Texas MD Anderson Cancer Center , from 75 per cent to 87.5 per cent.

CLINUVEL (ASX:CUV) has commenced dosing in a new preclinical study evaluating its proprietary controlled-release liquid injectable peptide formulation, VLRX-L.

In a significant cross-border collaboration, Australian company AdAlta (ASX:1AD) and its cellular immunotherapy subsidiary, AdCella, have entered into an agreement with Shanghai Cell Therapy Group to co-develop and commercialise a cutting-edge cancer treatment, BZDS1901, outside China.